LearnGlossaryMarketStocksSuperinvestorsSign in

DNA

Ginkgo Bioworks Holdings, Inc.

Healthcare · $444M market cap

Verdict

We can't put a fair value on DNA right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.

Business quality

1 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth—?
Equity per share growth-39.2% a year✗
Sales growth21.0% a year✓
Free cash flow growth—?
Return on invested capital-43.3%✗

Follow DNA

Track it on your watchlist and see the full analysis. Free.

Create a free account

Superinvestors

1 of the investors we track holds DNA. Who we track

Viking Global Investors

Viking Global Investors · as of Q2 2026

$35.4M

3,577,128 shares

About Ginkgo Bioworks Holdings, Inc.

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments. The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics, antibody developability, and small molecule developability, artificial intelligence…

Biotechnology

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works